Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

4′-Fluorouridine works against RNA-dependent RNA polymerase, an enzyme that helps viruses assemble RNA. The compound has a ...

Computational biologists from the National University of Singapore (NUS) have uncovered how RNA splicing—a crucial process ...

Dominique Verhelle is co-founder and CEO of the Brighton-based company NextRNA Therapeutics, which uses long non-coding RNA ...

After about five years working behind the scenes, Arrakis Therapeutics is unveiling that its lead program will aim to treat ...

Choosing a film for a movie night is always a battle. Now imagine if you could pick one that provided a window into some of ...

ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.

Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules ...

After 60 years of searching, geneticists have finally identified the gene behind the marmalade coloration in domestic cats.